In a patient with Gleason 4+3=7 (Grade Group 3) prostate cancer and intraductal carcinoma in multiple cores, how many weeks after the prostate biopsy should a contrast‑enhanced CT of the abdomen/pelvis and a technetium‑99m bone scan be performed, and are these studies required in addition to a PSMA PET/CT for staging?

Timing of CT and Bone Scan After Prostate Biopsy

For a patient with Gleason 4+3=7 (Grade Group 3) prostate cancer with intraductal carcinoma, staging imaging with CT abdomen/pelvis and bone scan should be performed as soon as clinically feasible after biopsy—typically within 1-2 weeks—and these studies remain indicated even when PSMA PET/CT is available, as they provide complementary staging information.

Risk Stratification and Imaging Requirements

Your patient has unfavorable intermediate-risk disease based on Grade Group 3 classification 1. The presence of intraductal carcinoma is particularly concerning, as this represents an independent adverse factor for metastasis and cancer-specific survival 1. Recent evidence shows that intraductal carcinoma is associated with larger tumor volumes and more aggressive disease 2, 3.

Recommended Imaging Approach

Conventional Imaging (CT and Bone Scan)

Both CT abdomen/pelvis and technetium-99m bone scan should be obtained for this patient 1, 4, 1. The 2024 EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines specifically recommend at least cross-sectional abdominopelvic imaging and bone scan for patients with Grade Group 3 disease 4. The 2022 AUA/ASTRO guidelines note that while robust evidence for unfavorable intermediate-risk disease remains lacking, clinicians may consider obtaining staging imaging for patients in this classification 1.

PSMA PET/CT Role

PSMA PET/CT should be performed IN ADDITION to conventional imaging, not as a replacement 4. The 2024 EAU guidelines recommend performing PSMA PET/CT "if available to increase accuracy" for intermediate-risk disease with Grade Group 3 4. PSMA PET/CT demonstrates 27% greater accuracy than conventional imaging for detecting nodal or distant metastasis 1, with sensitivity of 77% and specificity of 97% for lymph node involvement 4.

Critical Timing Considerations

There is no specified waiting period after biopsy before performing staging imaging. The guidelines do not mandate a delay between biopsy and staging scans 1, 4, 1. This differs from post-treatment PSA assessment, where waiting 6-8 weeks is recommended due to PSA half-life 5.

Proceed with staging imaging promptly (within 1-2 weeks of biopsy) to:

• Avoid treatment delays
• Complete staging workup efficiently
• Enable timely multidisciplinary treatment planning

Important Caveats Regarding Intraductal Carcinoma

The presence of intraductal carcinoma creates a unique challenge with PSMA PET imaging. Recent evidence shows that intraductal carcinoma may exhibit lower PSMA expression and reduced PSMA PET uptake compared to conventional adenocarcinoma 6, 7. In one study, 40% of patients with no intraprostatic PSMA uptake (PRIMARY score 1) had intraductal carcinoma on final pathology, and 100% of these patients had Grade Group ≥3 disease 7.

This means conventional imaging (CT and bone scan) becomes even more important in your patient, as PSMA PET may underestimate disease burden when intraductal carcinoma is present 6, 7.

Practical Algorithm

1. Obtain all three imaging modalities for this Grade Group 3 patient with intraductal carcinoma
2. Schedule within 1-2 weeks of biopsy—no mandatory waiting period
3. Order simultaneously: CT abdomen/pelvis with contrast, technetium-99m bone scan, and PSMA PET/CT
4. Interpret cautiously: If PSMA PET shows minimal uptake, do not assume low disease burden given the intraductal carcinoma component
5. Use conventional imaging findings to guide treatment decisions when PSMA PET and conventional imaging are discordant

The combination of all three modalities provides the most comprehensive staging assessment for this high-risk pathologic presentation 1, 4, 1.